Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nilotinib + peginterferon alfa-2a
- Development stage
- Unknown
- Lead developer
- Hospices Civils de Lyon
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Nilotinib + peginterferon alfa-2a is an investigational combination therapy being evaluated for the treatment of newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML). Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) that targets the BCR-ABL oncoprotein, while peginterferon alfa-2a is a long-acting formulation of interferon alpha that acts as an immunomodulator with anti-proliferative effects. The combination aims to achieve deeper and faster molecular responses compared to TKI monotherapy by combining direct oncogene inhibition with immune-mediated clearance of leukemic cells. Clinical evaluation has been primarily led by Hospices Civils de Lyon in the Phase II NILOPEG trial.
- Brand names
- Tasigna + Pegasys
- Other names
- nilotinib + pegylated interferon alpha 2anilotinib + Peg-IFN alpha 2a
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)DDR1 (Discoidin domain receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)PDGFRB (Platelet-derived growth factor receptor beta)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on nilotinib + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nilotinib + peginterferon alfa-2a.